Matches in SemOpenAlex for { <https://semopenalex.org/work/W2052384028> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2052384028 endingPage "49" @default.
- W2052384028 startingPage "41" @default.
- W2052384028 abstract "Thrombin-specific inhibitors directly diminish thrombin-induced coagulation and cellular activities without the side effects of heparin. Hirudin is the most potent natural thrombin-specific inhibitor. Recombinant hirudins (such as desirudin) have been shown to be effective in the treatment of heparin-induced thrombocytopenia (HIT) and in the prevention of thrombotic complications after hip or knee surgery. The application of recombinant hirudin has been limited mainly by hemorrhagic complications. Synthetic thrombin-specific inhibitors, including oligopeptides, tripeptides and non-peptide low molecular weight (LMW) thrombin inhibitors, have been designed according to their interactions with the active sites of thrombin. Bivalirudin (an anti-thrombin oligopeptide) has been approved for preventing thrombosis in unstable angina patients following angioplasty in adjunct to aspirin. Argotroban (a tripeptide thrombin inhibitor) has been used for the treatment of HIT, peripheral and cerebral thrombotic diseases. The benefit of using thrombin-specific inhibitors alone in acute myocardial infarction or unstable angina remains uncertain. A number of LMW thrombin-specific inhibitors have been developed. Some of them can be administrated orally, and cause less increase in bleeding time than other thrombin inhibitors. The efficacy, safety, stability and oral bioavailability of the thrombin inhibitors may be considerably improved through structural optimization. Most of the LMW thrombin inhibitors are currently being tested in animal models or at early stages of clinical trials. In this review, we will present an overview of recent advances in thrombin-specific inhibitors." @default.
- W2052384028 created "2016-06-24" @default.
- W2052384028 creator A5090824261 @default.
- W2052384028 date "2001-06-01" @default.
- W2052384028 modified "2023-09-23" @default.
- W2052384028 title "Development and Current Applications of Thrombin-specific Inhibitors" @default.
- W2052384028 doi "https://doi.org/10.2174/1568006013338123" @default.
- W2052384028 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12769663" @default.
- W2052384028 hasPublicationYear "2001" @default.
- W2052384028 type Work @default.
- W2052384028 sameAs 2052384028 @default.
- W2052384028 citedByCount "11" @default.
- W2052384028 crossrefType "journal-article" @default.
- W2052384028 hasAuthorship W2052384028A5090824261 @default.
- W2052384028 hasConcept C126322002 @default.
- W2052384028 hasConcept C164705383 @default.
- W2052384028 hasConcept C203014093 @default.
- W2052384028 hasConcept C2776301958 @default.
- W2052384028 hasConcept C2776710957 @default.
- W2052384028 hasConcept C2777292125 @default.
- W2052384028 hasConcept C2777557582 @default.
- W2052384028 hasConcept C2777565915 @default.
- W2052384028 hasConcept C2777785093 @default.
- W2052384028 hasConcept C2778271848 @default.
- W2052384028 hasConcept C2778382381 @default.
- W2052384028 hasConcept C2778810321 @default.
- W2052384028 hasConcept C2779161974 @default.
- W2052384028 hasConcept C2779612170 @default.
- W2052384028 hasConcept C2779630707 @default.
- W2052384028 hasConcept C2780400711 @default.
- W2052384028 hasConcept C2910323407 @default.
- W2052384028 hasConcept C500558357 @default.
- W2052384028 hasConcept C57002609 @default.
- W2052384028 hasConcept C71924100 @default.
- W2052384028 hasConcept C89560881 @default.
- W2052384028 hasConcept C98274493 @default.
- W2052384028 hasConceptScore W2052384028C126322002 @default.
- W2052384028 hasConceptScore W2052384028C164705383 @default.
- W2052384028 hasConceptScore W2052384028C203014093 @default.
- W2052384028 hasConceptScore W2052384028C2776301958 @default.
- W2052384028 hasConceptScore W2052384028C2776710957 @default.
- W2052384028 hasConceptScore W2052384028C2777292125 @default.
- W2052384028 hasConceptScore W2052384028C2777557582 @default.
- W2052384028 hasConceptScore W2052384028C2777565915 @default.
- W2052384028 hasConceptScore W2052384028C2777785093 @default.
- W2052384028 hasConceptScore W2052384028C2778271848 @default.
- W2052384028 hasConceptScore W2052384028C2778382381 @default.
- W2052384028 hasConceptScore W2052384028C2778810321 @default.
- W2052384028 hasConceptScore W2052384028C2779161974 @default.
- W2052384028 hasConceptScore W2052384028C2779612170 @default.
- W2052384028 hasConceptScore W2052384028C2779630707 @default.
- W2052384028 hasConceptScore W2052384028C2780400711 @default.
- W2052384028 hasConceptScore W2052384028C2910323407 @default.
- W2052384028 hasConceptScore W2052384028C500558357 @default.
- W2052384028 hasConceptScore W2052384028C57002609 @default.
- W2052384028 hasConceptScore W2052384028C71924100 @default.
- W2052384028 hasConceptScore W2052384028C89560881 @default.
- W2052384028 hasConceptScore W2052384028C98274493 @default.
- W2052384028 hasIssue "1" @default.
- W2052384028 hasLocation W20523840281 @default.
- W2052384028 hasLocation W20523840282 @default.
- W2052384028 hasOpenAccess W2052384028 @default.
- W2052384028 hasPrimaryLocation W20523840281 @default.
- W2052384028 hasRelatedWork W1482291463 @default.
- W2052384028 hasRelatedWork W1503293547 @default.
- W2052384028 hasRelatedWork W1986000434 @default.
- W2052384028 hasRelatedWork W2013018670 @default.
- W2052384028 hasRelatedWork W2052384028 @default.
- W2052384028 hasRelatedWork W2075550598 @default.
- W2052384028 hasRelatedWork W2115993405 @default.
- W2052384028 hasRelatedWork W2119813866 @default.
- W2052384028 hasRelatedWork W4231382193 @default.
- W2052384028 hasRelatedWork W4241624521 @default.
- W2052384028 hasVolume "1" @default.
- W2052384028 isParatext "false" @default.
- W2052384028 isRetracted "false" @default.
- W2052384028 magId "2052384028" @default.
- W2052384028 workType "article" @default.